Abstract
Urocortin comprises a group of endogenously produced peptide hormones that belong to the corticotropinreleasing factor (CRF) family with promising future as potential drugs for the treatment of heart disease. Members of the urocortin family are known to act as potent regulators of cardiac and vascular functions, through the activation of the CRF receptors that are highly expressed in heart and peripheral tissues. Urocortin exhibits potent vasodilatory effects in arteries from different species. These effects have been related to its capability to regulate the intracellular Ca2+ concentrations ([Ca2+]i) by different molecular mechanism. Beside, urocortin increases heart contractility and evokes positive inotropic and lusitropic effects by mechanisms involving different kinases signalling pathways. Urocortin peptides have also the ability to protect the heart from ischemia and reperfusion injuries by their improvement of post-ischemic cardiac performances, which include the recovery of heart contraction, the prevention from intracellular Ca2+ overload and the reduction of cardiac cell death. Furthermore, heart protection by urocortin involves the regulation of the transcription of specific genes acting to minimize mitochondrial damage, cell death, and oxidative stress. This review summarizes some of the recent findings related to the molecular mechanism underlying the role of urocortin in both vascular and cardiac function.
Keywords: Urocortin, vascular smooth muscle relaxation, positive inotropism, cardioprotection.
Current Vascular Pharmacology
Title:New Insights into the Mechanisms Underlying Vascular and Cardiac Effects of Urocortin
Volume: 11 Issue: 4
Author(s): Ignacio Diaz and Tarik Smani
Affiliation:
Keywords: Urocortin, vascular smooth muscle relaxation, positive inotropism, cardioprotection.
Abstract: Urocortin comprises a group of endogenously produced peptide hormones that belong to the corticotropinreleasing factor (CRF) family with promising future as potential drugs for the treatment of heart disease. Members of the urocortin family are known to act as potent regulators of cardiac and vascular functions, through the activation of the CRF receptors that are highly expressed in heart and peripheral tissues. Urocortin exhibits potent vasodilatory effects in arteries from different species. These effects have been related to its capability to regulate the intracellular Ca2+ concentrations ([Ca2+]i) by different molecular mechanism. Beside, urocortin increases heart contractility and evokes positive inotropic and lusitropic effects by mechanisms involving different kinases signalling pathways. Urocortin peptides have also the ability to protect the heart from ischemia and reperfusion injuries by their improvement of post-ischemic cardiac performances, which include the recovery of heart contraction, the prevention from intracellular Ca2+ overload and the reduction of cardiac cell death. Furthermore, heart protection by urocortin involves the regulation of the transcription of specific genes acting to minimize mitochondrial damage, cell death, and oxidative stress. This review summarizes some of the recent findings related to the molecular mechanism underlying the role of urocortin in both vascular and cardiac function.
Export Options
About this article
Cite this article as:
Diaz Ignacio and Smani Tarik, New Insights into the Mechanisms Underlying Vascular and Cardiac Effects of Urocortin, Current Vascular Pharmacology 2013; 11 (4) . https://dx.doi.org/10.2174/1570161111311040009
DOI https://dx.doi.org/10.2174/1570161111311040009 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Chest Pain in Children
Current Pediatric Reviews Flavonoids Isolated from Rumex aquaticus Exhibit Neuroprotective and Neurorestorative Properties by Enhancing Neurite Outgrowth and Synaptophysin
CNS & Neurological Disorders - Drug Targets Estrogen Receptors as Therapeutic Targets in Breast Cancer
Current Topics in Medicinal Chemistry Pharmacological Approaches of Alzheimer's Disease: An Update
Current Drug Therapy Brain Angiotensin and Cardiovascular Reactivity to Negative and Positive Emotional Stress
Current Hypertension Reviews Biodegradable Biomaterials
Recent Patents on Biomedical Engineering (Discontinued) Hypothyroidism and Nephrotic Syndrome: Why, When and How to Treat
Current Vascular Pharmacology The Effects of Creatine Supplementation and Physical Exercise on Traumatic Brain Injury
Mini-Reviews in Medicinal Chemistry Bioactive Polyphenols from Grapes and Wine Emphasized with Resveratrol
Current Pharmaceutical Design Hypertension in Patients with Severe Aortic Stenosis: Emphasis on Antihypertensive Treatment and the Risk of Syncope
Current Hypertension Reviews Bioactive Compounds for Effective Management of Drug-Resistant Tuberculosis
Current Bioactive Compounds Molecular Mechanisms of Neuronal Histamine and its Receptors in Obesity
Current Molecular Pharmacology Does Non-Alcoholic Fatty Liver Disease (NAFLD) Increase Cardiovascular Risk?
Endocrine, Metabolic & Immune Disorders - Drug Targets Alternative Pharmacological Interventions that Limit Myocardial Infarction
Current Medicinal Chemistry Whole Cell Biocatalysts for the Preparation of Nucleosides and their Derivatives
Current Pharmaceutical Design Genetics of Ion Channels in Sudden Unexplained Death Syndrome: Moving Beyond Idiopathic Reactions To Personalized Risk Assessment
Current Pharmacogenomics and Personalized Medicine Apolipoprotein B and Apolipopotein A-I in Vascular Risk Prediction-A Review
Current Pharmaceutical Design Barriers to Optimising Prescribing and Deprescribing in Older Adults with Dementia: A Narrative Review
Current Clinical Pharmacology Cardiac Nuclear Imaging: Current Status and Future Directions
Current Medical Imaging Treatment of Obesity: Should We Target the Individual or Society?
Current Pharmaceutical Design